Q1 2026 Consolidated Preliminary: Operating Profit +120%, Net Income +1,376%


  • Q1 2026 consolidated preliminary results: Sales 141,997 million KRW (YoY +4.4%, QoQ -3.4%), Operating profit 9,227 million (+120%, +16.4%), Net income 7,376 million (+1,376.6%, +31.6%)
  • Majority interest net income: 8,269 million (+704.7% YoY, +14.3% QoQ)
  • Preliminary figures subject to change after external audit

KOSPI Filing Information


  • Filing: Consolidated Financial Statements Basis Operating (Provisional) Results (Fair Disclosure)
  • Company: Ildong Pharmaceutical (249420)
  • Submission: Ildong Pharmaceutical Co., Ltd.
  • Receipt: 05-13-2026
  • Under KRX KOSPI Market Division